Mar 26 |
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
|
Mar 14 |
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
|
Feb 28 |
Dyadic announces strategic partnership agreement to develop rabies vaccines
|
Feb 28 |
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
|
Feb 13 |
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
|
Feb 6 |
Dyadic signs R&D agreement with global biopharmaceutical company
|
Feb 6 |
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
|
Feb 1 |
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
|
Jan 22 |
Dyadic International, Inc Invites You to Join Us at The Microcap Conference
|
Jan 2 |
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
|